Cytoreductive surgery with liver‐involved renal cell carcinoma

Abstract

The purpose of this study was to demonstrate the benefits of cytoreductive surgery for renal cell carcinomas that also involve the liver. Between 1994 and 1997, four patients with renal cell carcinoma with liver involvement were surgically treated with nephrectomy and hepatectomy. Two of them underwent a simultaneous hepatectomy and nephrectomy (group 1), and the remaining two patients underwent a hepatectomy after a nephrectomy and had a diagnosis of postoperative recurrence (group 2). Two patients, one from each group, died of multiple bone metastasis and lung metastasis 30 months and 12 months after the hepatectomy; the second patient from group 1 died 40 months after the first operation due to gastrointestinal hemorrhaging. The second patient from group 2 displayed no evidence of recurrence 18 months after the second surgical procedure. The survival rates for these patients were 66% and 33% at 1 and 3 years, respectively. Autopsy studies revealed that one patient from group 2 had a local recurrence in the liver while the other two patients from group 1 did not. Our results suggested that a progressive approach may therefore be useful for patients demonstrating renal cell carcinoma where there is liver involvement.

Outcome following hepatic resection of metastatic renal tumors: the Paul Brousse Hospital experience

“…Although relatively few patients present with a metastatic disease pattern that is amenable to a curative surgical approach, we and others have previously identified subsets of patients who achieve long‐term survival following hepatic resection. A review of the literature identifies 15 reports describing surgical treatment of hepatic metastases from renal cancer published from 1978 to 2005 (Table I) 1–15 . Combined, these series provide survival data following hepatic resections for renal cancer metastases in 64 patients.…”

Repetitive transarterial chemoembolization (TACE) of liver metastases from renal cell carcinoma: Local control and survival results

“…Median survival up to 48 months could be achieved [21][22][23][24]. The 3-year survival estimates for patients treated by chemotherapy and interferon were 15 and 48%, respectively [17].…”

Tumor renal con invasión hepática: aportación de un nuevo caso y revisión de la literatura

“…Kazugoshi et al 6 presentan 2 pacientes que tras nefrectomía y extirpación de segmentos VI y VII hepáticos se encuentran libres de enfermedad a 100 y 57 meses tras la cirugía. Otro estudio realizado en 4 pacientes presenta supervivencia global a 1 y 3 años tras la cirugía del 66% y 33% respectivamente 15,21,22 .…”